pyrazines has been researched along with Familial Primary Pulmonary Hypertension in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeev, SN; Nekludova, GV; Proshkina, AA; Tsareva, NA | 1 |
| Furukawa, A; Goto, M; Iwahori, H; Kawamura, A; Ohashi, N; Okabe, T; Tamura, Y | 1 |
| Greene, RA | 1 |
| Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, ZS; Zhang, X; Zhang, ZH; Zhu, XB | 1 |
| Lang, IM; Skoro-Sajer, N | 1 |
| Chin, KM; Hardin, EA | 1 |
| Bonderman, D; Degano, B; Delcroix, M; Efficace, M; Galiè, N; Giorgino, R; Hoeper, MM; Karlócai, K; Kurzyna, M; Lang, IM; Simonneau, G; Torbicki, A | 1 |
2 review(s) available for pyrazines and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Receptors, Prostaglandin; Signal Transduction | 2014 |
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines; Tachyphylaxis | 2016 |
1 trial(s) available for pyrazines and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Adult; Aged; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2012 |
4 other study(ies) available for pyrazines and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
[Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)].
Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Female; Humans; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Humans; Prospective Studies; Pyrazines; Pyrimidines; Sulfonamides | 2017 |
Safety concerns regarding selexipag in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines | 2018 |
The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension.
Topics: Animals; Blood Flow Velocity; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; I-kappa B Proteins; Lung; Male; NF-KappaB Inhibitor alpha; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Transcription Factor RelA | 2014 |